

Combined Form PTO/08A&B				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				Application Number	Not yet assigned
				Confirmation Number	
				Filing Date	August 24, 2006
				First Named Inventor	Takahide KOHRO et al.
				Art Unit	
Sheet 1 of 1				Examiner Name	
				Attorney Docket Number	032218A

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code <sup>2</sup> (if known)		
		US			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation*
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.				Translation*
	1	KATSUHIKO MASAMURA et al., "Pitavastatin-Induced Thrombomodulin Expression by Endothelial Cells Acts Via Inhibition of Small G Proteins of the Rho Family", Arterioscler. Thromb. Vasc. Biol., Vol. 23, No. 3, pp. 512-517 (2003)				
	2	SHIGERU MORIKAWA et al., "The Effect of Statins on mRNA Levels of Genes Related to Inflammation, Coagulation, and Vascular Constriction in HUVEC", Human Umbilical Vein Endothelial Cells, J. Atheroscler. Thromb., Vol. 9, No. 4, pp. 178-183 (2002)				
	3	MARK F. MCCARTY et al., "Reduction of serum C-reactive protein by statin therapy may reflect decreased isoprenylation of Rac-1, a mediator of the IL-6 signal transduction pathway", Med. Hypotheses, Vol. 60, No. 5, pp. 634-639 (2003)				
	4	R.P. BRANDES et al., "Withdrawal of Cerivastatin Induces Monocyte Chemoattractant Protein 1 and Tissue Factor Expression in Cultured Vascular Smooth Muscle Cells", Arterioscler. Thromb. Vasc. Biol., Vol. 23, No. 10, pp. 1794-1800 (2003)				
	5	ANDREAS H. WAGNER et al., "Improvement of Nitric Oxide-Dependent Vasodilatation by HMG-CoA Reductase Inhibitors Through Attenuation of Endothelial Superoxide Anion Formation", Arterioscler. Thromb. Vasc. Biol., Vol. 20, No. 1, pp. 61-69 (2000)				
	6	MASAO TAKEMOTO et al., "Pleiotropic Effects of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors", Arterioscler. Thromb. Vasc. Biol., Vol. 21, No. 11, pp. 1712-1719 (2001)				
	7	MASATO ETO et al., "Modulation of Coagulation and Fibrinolytic Pathways by Statins", Endothelium, Vol. 10, No. 1, pp. 35-41 (2003)				
	8	MICHAL MYSLIWIEN et al., "Statin therapy - more than lipid - lowering effect", Advances in Clinical and Experimental Science, Vol. 12, No. 2, pp. 185-190 (2003)				
	9	CARMINE VECCHIONE et al., "Withdrawal of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Elicits Oxidative Stress and Induces Endothelial Dysfunction in Mice", Circulation Research, Vol. 91, No. 2, pp. 173-179 (2002)				
	10	MARINA CAMERA et al., "Cholesterol-induced Thrombogenicity of the Vessel Wall: Inhibitory Effect of Fluvastatin", Thrombosis and Haemostasis, Vol. 87, No. 4, pp. 748-755 (2002)				
	11	International Search Report mailed June 7, 2005 of International Application PCT/JP2005/002993				
Examiner Signature		/Craig Ricci/		Date Considered	03/30/2009	

\*EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to indicate here if English language Translation is attached.